Telomerase Drives Gut Inflammation Through a Surprising Non-Telomere Pathway
TERT, the enzyme that extends telomeres, directly fuels inflammation via the cGAS-STING immune pathway — independent of its classic role.
Summary
Scientists have discovered that TERT — the catalytic subunit of telomerase, long studied for its role in extending telomeres — also directly regulates inflammation through the cGAS-STING innate immune pathway. Using mouse and zebrafish models of gut inflammation, plus human colitis and Crohn's disease tissue samples, researchers found this function is evolutionarily conserved. Critically, a knock-in mouse model with reverse-transcriptase-inactive TERT showed inflammation still occurs, meaning this role is entirely independent of telomerase's DNA-synthesizing activity. A specific myeloid immune cell subpopulation called T-MAC was identified as the key cellular player, where TERT amplifies STING activation and triggers type 1 interferon responses. These findings reframe TERT as a direct immune regulator and open therapeutic avenues beyond cancer.
Detailed Summary
Telomerase is best known for maintaining chromosome ends and enabling cellular immortality in cancer. Its reverse transcriptase subunit, TERT, has therefore been viewed primarily as a cancer target. This study challenges that narrow view by revealing a conserved, non-canonical inflammatory role for TERT that operates completely independently of its enzymatic activity.
The research team used multiple complementary model systems — murine gut inflammation models, zebrafish models, and human tissue samples from colitis and Crohn's disease patients — to establish that TERT's pro-inflammatory function is evolutionarily conserved across species. This cross-species validation substantially strengthens confidence in the relevance of findings to human disease.
A critical mechanistic insight came from the TERTVAA knock-in mouse, in which TERT is rendered reverse-transcriptase-inactive but still expressed from its endogenous locus. Inflammation persisted in these animals, ruling out telomere lengthening or RNA synthesis as the mechanism. Instead, TERT was found to enhance activation of the cGAS-STING cytosolic DNA-sensing pathway, which in turn drives type 1 interferon production — a central arm of innate immune signaling.
Using single-cell approaches, the team identified a previously uncharacterized myeloid subpopulation they named T-MAC (TERT-expressing Myeloid-Associated Cells) as the key cellular context where this regulation occurs. Within T-MACs, TERT acts as a cell-type-specific amplifier of STING signaling, linking the enzyme to chronic inflammatory disease mechanisms.
The implications extend well beyond cancer biology. Targeting TERT or the TERT-STING axis in inflammatory diseases such as IBD could represent a novel therapeutic strategy. However, since the study relied on abstract-level data, finer mechanistic details — including exactly how TERT interfaces with cGAS-STING proteins — remain to be fully characterized in the complete publication.
Key Findings
- TERT directly activates the cGAS-STING innate immune pathway independent of its reverse transcriptase activity.
- Reverse-transcriptase-inactive TERT (TERTVAA knock-in mice) still drives gut inflammation, decoupling immunity from telomere maintenance.
- A newly identified myeloid subpopulation, T-MAC, is the cell type where TERT amplifies STING and type 1 interferon responses.
- This TERT inflammatory function is evolutionarily conserved across mice, zebrafish, and human colitis/Crohn's disease samples.
- Findings provide therapeutic rationale for targeting TERT in inflammatory bowel disease, not just in cancers.
Methodology
The study employed murine and zebrafish gut inflammation models alongside human colitis and Crohn's disease tissue samples. A novel TERTVAA knock-in mouse expressing catalytically inactive TERT from its endogenous locus was central to separating enzymatic from non-enzymatic functions. Molecular, pharmacological, and single-cell transcriptomic approaches were used to characterize the T-MAC subpopulation and the TERT-STING regulatory axis.
Study Limitations
Only the abstract was available, so specific mechanistic data, effect sizes, and full methodology cannot be critically evaluated. It is unclear how TERT physically interacts with cGAS-STING components at the molecular level. The translational relevance to human therapy requires further validation in clinical or ex vivo human immune cell models.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.